Validity of neonatal jaundice evaluation by primary health-care workers and physicians in Karachi, Pakistan by Hatzenbuehler, L. et al.
ORIGINAL ARTICLE
Validity of neonatal jaundice evaluation by primary health-care
workers and physicians in Karachi, Pakistan
L Hatzenbuehler1, AKM Zaidi2, S Sundar2, S Sultana2, F Abbasi2, A Rizvi1,2 and GL Darmstadt1
1Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA and
2Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan
Objective: The purpose of this study was to validate primary health-care
workers’ and physicians’ visual assessment of neonatal hyperbilirubinemia
in Karachi, Pakistan.
Study Design: We compared primary health-care workers’ and
physicians’ clinical identification of jaundice in infants <60 days old.
Result: Primary health-care workers identified 1- to 20-day-old neonates
with hyperbilirubinemiaX15 mg per 100 ml (260 mmol l1) with 83.3%
sensitivity and 50.5% specificity; neonates aged 1 to 6 days were identified
with 76.2% sensitivity and 60.7% specificity. Physicians identified neonates
aged 1 to 20 days with hyperbilirubimemia X15 mg per 100 ml
(260 mmol l1) with 51.4% sensitivity and 90.7% specificity, and neonates
aged 1 to 6 days with 50% sensitivity and 88.5 % specificity. The primary
health-care workers’ and physicians’ assessments showed fair
interobserver agreement (k statistic 0.29).
Conclusion: Primary health-care workers identified hyperbilirubinemic
neonates with adequate sensitivity. With proper training and supervision,
their assessment could improve the referral of hyperbilirubinemic
neonates in low-resource settings in the developing world.
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Introduction
Delay in the diagnosis and treatment of neonatal
hyperbilirubinemia, due to inadequate health worker recognition of
jaundice or lack of proper diagnostic equipment, is common in
developing countries and leads to preventable cases of
neurodevelopmental impairment, disability and sometimes death.1
The risk of damage to the neurological system due to
hyperbilirubinemia, a condition known as kernicterus, increases
with (1) early exposure to high serum bilirubin levels, (2)
prematurity or low birth weight, (3) rapid progression of jaundice,
(4) high peak levels and (5) prolonged length of exposure
to high levels.2
Currently, no international protocol exists to aid in primary
health-care worker (HCW) identification of infants with clinically
significant jaundice in developing country settings. Preliminary
results from a study by Goswami et al.3 in 2006, who studied the
use of the World Health Organization’s Integrated Management of
Childhood Illness (IMCI) algorithm for the diagnosis of severe
illness in young infants, showed that infants with severe jaundice
were commonly missed. The authors concluded: ‘the sensitivity of
the IMCI algorithm can be further increased if yellowness of lower
extremities/palms/soles is included in the algorithm.’3
One tool considered for integration into the IMCI algorithm is
the clinical jaundice scale, originally introduced by Kramer.4 The
scale is used to predict the severity of hyperbilirubinemia based on
the zone of skin discoloration in the neonate extending from the
head (zone 1) to the palms and soles (zone 5), and assumes that
an increasing zone of staining corresponds to increasing levels of
serum bilirubin.4 Studies by Ebbesen5 found that neonatal jaundice
appearing in Kramer scale zone 4 or higher (that is, icterus
progression to the knees (zone 4) and then to the palms and soles
(zone 5)) was correlated with clinically significant serum bilirubin
levels, on average X11.0 mg per 100 ml (188 mmol l1), and
signaled the need for further evaluation and treatment at a tertiary
care center.5 The Kramer scale, or an adapted version, is widely
used by physicians worldwide to predict the necessity of more
sophisticated testing to rule out hyperbilirubinemia, and may be
particularly advantageous in low-resource settings.
Previous studies have examined the clinical assessment of
jaundice by various cadres of HCWs, but none have been
conducted, similar to this study, in a developing country to
compare HCW and physician (PHY) clinical evaluations of
neonatal hyperbilirubinemia (Supplementary Table 1).5–12
We evaluated the validity of an adapted Kramer scale when used
by HCW and PHY to evaluate infants <60 days of age, with a focus
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on neonates aged 1 to 20 days, presenting to community clinics in
Karachi, Pakistan.
Methods
Data collection occurred between September 2004 and March 2005
as a prospective surveillance study involving a multiethnic
population of infants presenting to three primary health-care
clinics (Rehri Goth, Bilal Colony and Ibrahim Hyderi) in Karachi,
Pakistan (area population B170 000). The study used the
infrastructure of the Young Infant Clinical Signs Study aimed to
identify clinical signs of illness signaling need for urgent referral to
hospital.13
Infants <60 days of age who were brought to the study clinics
for evaluation of suspected illness were initially consented and
screened for clinical signs of illness, including jaundice, according
to the Young Infant Clinical Signs Study protocol.13 At each of the
three primary health-care clinics, irrespective of their presenting
clinical complaint, each infant was first evaluated by an HCW
(n¼ 3), each of whom were lady health visitors with 2 years of
formal health training with additional training in neonatal illness
recognition. Each infant was then taken, in a blinded fashion, to a
separate room of the clinic, and independently assessed by a PHY
(n¼ 5) who had a minimum of 6 months of postgraduate
residency work experience in pediatrics in a tertiary hospital.
Infants were observed unclothed, under indoor lighting augmented
by natural daylight from clinic windows. After visual assessment
and application of skin pressure, we independently assigned
jaundice scores to each infant (Supplementary Figure 1). Infants
determined to have clinically significant signs of jaundice or
requiring hospitalization for other reasons were referred to the
National Institute of Child Health for appropriate laboratory testing
and treatment. Blood for serum bilirubin sampling was collected
and then transported in a cool container to the Aga Khan
University Laboratory. Samples were processed with a reagent
supplied by Beckman Synchron (Brea, CA, USA), and total bilirubin
was measured by timed end point using the Diazo method (4.5%
coefficient of variation).
Infants were excluded if they were (1) living outside the defined
study area, (2) previously enrolled in the study, (3) recently
hospitalized (<2 weeks), (4) referred from a health facility, (5)
found to have an obvious lethal malformation, (6) in need of
immediate cardiopulmonary resuscitation or (7) unable to provide
informed consent. In addition, the sensitivity and specificity
analysis excluded infants <1 day and >20 days old and those for
whom a bilirubin sample was not obtained. The Kappa (k) statistic
analysis excluded those without two independent Kramer scale
scores assigned by an HCW and a PHY.
Approval for this study was obtained from the institutional
review board at the Johns Hopkins Bloomberg School of Public
Health, and the ethical review committee at Aga Khan University.
Data analysis
In those infants who received serum bilirubin testing, sensitivity
and specificity calculations compared the HCW and PHY use of the
Kramer scale in neonates aged 1 to 20 days, and separately for
neonates aged 1 to 6 days and those aged 7 to 20 days, using
serum bilirubin as the gold-standard measure at two levels of
X15 mg per 100 ml (260 mmol l1) and X20 mg per 100 ml
(340mmol l1). The serum bilirubin thresholds of 15 mg per
100 ml (260 mmol l1) and 20 mg per 100 ml (340 mmol l1)
approximated levels of hyperbilirubinemia, based on a standard
American Academy of Pediatrics Clinical Practice Guideline
nomogram applicable to normal birth-weight infants, that signal
need for referral, the former for consideration for phototherapy and
the latter for exchange transfusion.14 These levels are intermediate
or high risk in any infant aged >24 h irrespective of other
associated risk factors. Serum bilirubin levels <15 mg per 100 ml
(260mmol l1) and X15 mg per 100 ml (260mmol l1) were
compared to assigned Kramer scale scores of 1 to 3 (jaundice of
face, chest, abdomen or thighs, and considered to correlate with a
serum bilirubin level <15 mg per 100 ml (260 mmol l1)) and
Kramer scale scores of 4 to 5 (jaundice of the distal extremities,
including the legs below the knees (level 4) or the palms and soles
(level 5), and indicative of need for referral for evaluation for
hyperbilirubinemia, likelyX15 mg per 100 ml (260mmol l1)).15
Serum bilirubin levels <20 mg per 100 ml (340mmol l1) and
X20 mg per 100 ml (340 mmol l1) were compared to assigned
Kramer scale scores of both 1 to 3 and 4 to 5, and 1 to 4 and 5
(jaundice extending to the palms and soles, considered as
indicative of need for urgent referral and likely hyperbilirubinemia
X20 mg per 100 ml (340 mmol l1)) (Supplementary Figure 1).
Interobserver percent agreement and weighted k statistics
compared the clinical assessment of each infant individually by
both an HCW and a PHY, first in all infants aged <60 days, and
then separately for neonates aged 1 to 6 days and 7 to 20 days.
Calculation of agreement and k statistics was based on two
dichotomous categorizations of infants. The first percent agreement
calculations examined jaundice of the distal extremities (Kramer
scale score 4 or 5) and thus needing referral-level evaluation vs
jaundice limited to the face, chest, abdomen and thighs (Kramer
scale score 1 to 3). The second percent agreement calculations
examined a Kramer scale score of 5 vs a score of
1 to 4. k Statistics of <0, 0.0 to 0.20, 0.21 to 0.40, 0.41 to 0.60,
0.61 to 0.80, and 0.81 to 1.00 were considered as poor, slight, fair,
moderate, substantial and almost perfect agreement, respectively.16
Statistical analysis was performed using Stata (version 10)
software (StataCorp, College Station, TX, USA).17
Results
A total of 976 infants (Rehri Goth (n¼ 304), Bilal (n¼ 549) and
Ibrahim Hyderi (n¼ 123)) aged <60 days were enrolled and
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evaluated for clinical signs of jaundice; 961 were evaluated and
assigned a Kramer scale score by an HCW, and 925 were
independently evaluated by a PHY (Figure 1). A total of 910 infants
were assigned two independent Kramer scale scores. Among those
in whom serum bilirubin sampling was obtained, over 98% were
exclusively breastfed, and 90% were considered aseptic, acyanotic,
non-tachypneic, non-hypoxic and had normal temperature
(Supplementary Tables 2 and 3).
Among 193 infants (20.9%, 193/925) identified with jaundice, a
serum bilirubin sample was collected in 143 infants; the remaining
infants refused referral or did not provide consent for obtaining
blood. Of these 143 infants, 137 were 1 to 20 days of age and were
referred from the following study sites: Rehri Goth (n¼ 14), Bilal
(n¼ 119) and Ibrahim Hyderi (n¼ 4). Of the three study sites,
Bilal is considered the best equipped for laboratory blood draws, is
located closest to the referral hospital and has a higher rate of
referral acceptance. Among infants aged 1 to 20 days, the median
and mean bilirubin levels were 11.8 mg per 100 ml (201 mmol l1)
and 12.8 mg per 100 ml (216 mmol l1), respectively, and the
range was 1 to 28.6 mg per 100 ml (17 to 489mmol l1).
Infants evaluated for study eligibility: Aged <60 days (n=976)
Infants enrolled: receipt of independent Kramer scale score assignments by HCW and PHY
HCW Kramer scale score (n=961)        PHY Kramer scale score (n=925)
Infants with 2 independent Kramer scale scores (n= 910)
Analysis: Kappa score & percent agreement calculation
n=902 (age <60 days)
Excluded: (n=24) (<1d & >20 d)
Analysis: kappa score & percent agreement calculation
by age subgroups, age 1-20 days (n=878)
Age 1-6 days (n=613)
Serum bilirubin sample obtained n=143
Excluded: (n=767) (No serum bilirubin sample)
Excluded (n=6) > 20 days old 
Bilirubin ≥15 mg/dL (270 µmol/L) (n= 36)
Bilirubin ≥ 20 mg/dL (340 µmol/L) (n= 7)
Analysis: Sensitvity and specificity calculations
Infants evaluated by HCW (n=137)
Infants evaluated by PHY (n=132)
Analysis: Sensitivity and specificity calculations within age subgroups 
Infants aged 1-6 days (n=77)
Infants evaluated by HCW (n=77)
Infants evaluated by PHY (n= 72)
Excluded: (n=66) <2 Kramer scores
Age 7-20 days (n= 265)
Bilirubin <15 mg/dL (270 µmol/L) (n=101)
Bilirubin <20 mg/dL (340 µmol/L) (n=130)
Infants aged 7-20 days: (n= 60)
Infants evaluated by HCW (n=60)
Infants evaluated by PHY (n=60)
Figure 1 Sample flowchart.
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Thirty-six infants 1 to 20 days old (26.3%) were found to have a
serum bilirubin level X15 mg per 100 ml (260 mmol l1), and 7
(5.1%) were found to have a serum bilirubin level X20 mg per
100 ml (340mmol l1), which were considered high bilirubin
levels necessitating referral irrespective of age of the infant
(Supplementary Figures 2 and 3).
Sensitivity and specificity of clinical assessments of jaundice
Primary health-care workers. Among the 36 neonates 1 to 20
days of age with serum bilirubin level X15 mg per 100 ml
(260 mmol l1), the HCWs assigned 30 neonates a Kramer scale
score of 4 or 5, signaling need for referral (sensitivity 83.3%)
(Table 1). HCW clinical assessments were less specific, as among
101 neonates with a serum bilirubin level <15 mg per 100 ml
(260 mmol l1), 51 were assigned a Kramer scale score of 1 to 3
(specificity 50.5%). Similarly, the HCW assessments corresponded
with sensitivity of 76.2 and 93.3%, but specificity of 60.7 and 37.8 %
in the separate age groups, 1 to 6 days and 7 to 20 days,
respectively.
Among the seven neonates who were found to have a serum
bilirubin level X20 mg per 100 ml (340 mmol l1), the HCWs
were 71.4% sensitive and 42.3% specific in assigning a Kramer
scale score of 4 or 5 (Table 1). Similar results were found among
the separate age categories of neonates. The HCWs were 57.1%
sensitive and 81.7% specific in assigning these seven neonates a
Kramer score of 5 (Table 2). Within the age category 1 to 6 days,
HCWs were 60.0% sensitive and 84.7% specific in assigning a
Kramer scale score of 5 to neonates who had a serum bilirubin
levelX20 mg per 100 ml, and 50% sensitive and 77.6% specific for
neonates aged 7 to 20 days.
Physicians. Among the 36 neonates aged 1 to 20 days who had a
serum bilirubin value X15 mg per 100 ml (260mmol l1), PHYs
evaluated 35 of the neonates and assigned 18 (sensitivity 51.4%) a
Kramer score of 4 or 5 (Table 1). Conversely, among 97 neonates
with a serum bilirubin level <15 mg per 100 ml (260 mmol l1),
PHYs assigned a Kramer scale score of 1 to 3 in 88 (specificity
90.7%). Similarly, PHY assessments corresponded with moderate
sensitivity (50.0 and 53.3%, respectively) and high specificity (88.5
and 93.3%, respectively) in the separate age groups, 0 to 6 days and
7 to 20 days.
Among the seven neonates who were found to have a serum
bilirubin level X20 mg per 100 ml (340mmol l1), PHYs were
57.1% sensitive in assigning them a Kramer scale score of 4 to 5, and
81.6% specific. Among those neonates aged 1 to 6 days, PHYs were
80.0% sensitive and 82.1% specific. Neither of the two infants aged
7 to 20 days was correctly assigned a Kramer scale score of 4 to
5, but PHYs correctly ruled out clinical signs of jaundice in 81.0%.
At a Kramer score cutoff of 5 (jaundice in the palms and soles),
PHYs were 57.1% sensitive in assigning these seven neonates a
Table 1 Sensitivity and specificity of clinical assessments of jaundice reaching a Kramer score of 4 or 5 by HCWs and PHYs at serum bilirubin thresholdsX15 mg per
100 ml (260 mmol l1) and X20 mg per 100 ml (340 mmol l1)
Evaluator Serum bilirubin threshold
X15mg per 100ml (260 mmol l1)
Serum bilirubin threshold
X20mg per 100ml (340 mmol l1)
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
All infants 1–20 days (n¼ 137)
HCW (n¼ 137) (30/36) 83.3 (51/101) 50.5 (5/7) 71.4 (55/130) 42.3
PHY (n¼ 132) (18/35) 51.4 (88/97) 90.7 (4/7) 57.1 (102/125) 81.6
Infants 1–6 days (n¼ 77)
HCW (n¼ 77) (16/21) 76.2 (34/56) 60.7 (3/5) 60.0 (37/72) 51.4
PHY (n¼ 72) (10/20) 50.0 (46/52) 88.5 (4/5) 80.0 (55/67) 82.1
Infants 7–20 days (n¼ 60)
HCW (n¼ 60) (14/15) 93.3 (17/45) 37.8 (2/2) 100.0 (18/58) 31.0
PHY (n¼ 60) (8/15) 53.3 (42/45) 93.3 (0/2) 0.0 (47/58) 81.0
Abbreviations: HCW, primary health-care worker; PHY, physician.
Table 2 Sensitivity and specificity of clinical assessments of jaundice reaching a
Kramer score of 5 by HCWs and PHYs at serum bilirubin threshold X20 mg per
100 ml (340 mmol l1)
Evaluator Sensitivity (%) Specificity (%)
All infants 1–20 days (n¼ 137)
HCW (n¼ 137) (4/7) 57.1 (106/130) 81.6
PHY (n¼ 132) (4/7) 57.1 (119/125) 95.2
Infants 1–6 days (n¼ 77)
HCW (n¼ 77) (3/5) 60.0 (61/72) 84.7
PHY (n¼ 72) (4/5) 80.0 (64/67) 95.5
Infants 7–20 days (n¼ 60)
HCW (n¼ 60) (1/2) 50.0 (45/58) 77.6
PHY (n¼ 60) (0/2) 0 (55/58) 94.8
Abbreviations: HCW, primary health-care worker; PHY, physician.
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Kramer score of 5 and 95.2% specific (Table 2). Among the five
neonates aged 1 to 6 days, PHYs correctly assigned 80.0% a Kramer
score of 5; specificity was 95.5%. Only two infants aged 7 to 20 days
had serum bilirubin levels X20 mg per 100 ml (340mmol l1),
neither of whom was identified by PHYs, but 94.5% of those with
serum bilirubin levels <20 mg per 100 ml (340 mmol l1) were
correctly assigned a Kramer scale <5.
Intraobserver agreement and kappa statistics
There was fair interobserver agreement between HCWs and PHYs in
the use of the Kramer scale when assessing jaundice in infants
<60 days of age (Table 3). Agreement of 67.7% corresponded with
Kramer scale assignments in zones 1, 2 or 3 and Kramer scale
assignments 4 or 5, which resulted in a k statistic of 0.29.15
Similar results were seen among neonates 1 to 20 days, and in the
two age groups, 1 to 6 days and 7 to 20 days.
Discussion
The primary limitations of this study are related to its conduct in a
low-resource setting in a developing country community setting,
where socioeconomic and cultural barriers impede neonatal care.
Only 16% of the infants independently evaluated by HCW and PHY
for any illness received serum bilirubin measurements (143/910).
Ideally, all infants should have received a serum bilirubin
measurement, regardless of whether they had evidence of clinical
jaundice, to validate HCW and PHY visual assessments of neonatal
hyperbilirubinemia in our population sample. However, blood
was only obtained if a PHY identified the presence of any level of
jaundice (Kramer score X1) and the family provided consent for
obtaining blood. Of the 910 newborns with two independent
assessments by an HCW and a PHY, 17% (153/910) were judged
by a PHY to have no jaundice (Kramer score 0); none of these
patients had a blood sample taken for bilirubin determination.
Of the 196 infants with a PHY Kramer score assignment of 4 to 5,
only 13% (26/196) obtained a blood draw. Despite this limitation,
our data provide some useful information on the performance of
the Kramer scale as a screening tool in a low-resource setting.
Although previous studies have examined the clinical
assessment of jaundice by HCWs, trained nurses and PHYs, none
have been conducted in a developing country to compare HCW and
PHY clinical evaluations of neonatal hyperbilirubinemia. Most
previous studies on the clinical assessment of neonatal
hyperbilirubinemia were conducted in the United States or Europe,
were limited to a single or bi-ethnic study population and
evaluated the clinical assessment of jaundice by a single observer
compared to a serum bilirubin measurement taken in all the
enrolled subjects (Supplementary Table 1).5–12
Riskin et al.6 showed that neonatologists’ identification of
jaundice, and predicted serum bilirubin levels based on the Kramer
scale, was highly correlated with serum total bilirubin levels
(r¼ 0.682, P<0.001). This study concluded: ‘the clinical
impression of jaundice by anyexperienced clinician is a reliable
method to assess newborns for y(neonatal hyperbilirubinemia)
and serum bilirubin levels are necessary only in severely jaundiced
neonates.’ Similarly, Madlon-Kay et al.7,8 found that nurses trained
in clinical assessment of jaundice adequately (r¼ 0.61, P<0.01)
identified newborns with total serum bilirubin levels <12 mg per
100 ml (205 mmol l1), and all three infants with serum bilirubin
levels X17 mg per 100 ml (290mmol l1) as having jaundice
requiring referral to hospital. Szabo et al.9,10 reported that trained
nurses and PHYs were able to identify neonates with jaundice
that did not reach the abdomen or extremities in whom
hyperbilirubinemia did not exceed 250 mmol l1.
Alternatively, multiple studies have contested the validity of HCW
diagnosis of hyperbilirubinemia using a jaundice scale. Knudsen
and Brodersen11 concluded that the yellow color of the skin is
influenced by basal skin color, albumin binding capacity and
serum pH, and is therefore an unreliable surrogate of plasma
bilirubin levels. Studies by Moyer et al.12 and Knudsen and
Brodersen11 have challenged the accuracy and reliability of
Kramer’s scale and found a poor correlation between PHY
observations and total serum bilirubin levels (r¼ 0.16 to 0.24).
Despite these limitations, they concluded that PHY clinical
observations were 97% specific in identifying infants who are not
likely to have bilirubin levels >12 mg per 100 ml (205 mmol l1),
based on verification that jaundice did not extend below the nipple
line. On the basis of these and other studies, it is standard practice
in the United States and abroad to clinically evaluate every infant
for jaundice before both additional testing and discharge from the
hospital. Many studies support the scale as a valid preliminary
screening tool (Supplementary Table 1).5–12
This study showed that a clinical assessment tool used to
identify infants with jaundice extending to the distal extremities
shows some promise for guiding referral of infants with moderate
to severe hyperbilirubinemia in a developing country setting, where
sophisticated and expensive equipment is not widely available.7–11
HCWs identified both infants aged 1 to 20 days (sensitivity 83.3%)
and those <1 week old (aged 1 to 6 days) (sensitivity 76.2%) with
Table 3 Percent agreement and k statistic calculations to compare the clinical
use of the Kramer scale by HCW to PHY
Percent
agreement
(%)
Expected
agreement
(%)
k
statistic
Standard
error
Kramer score grouping: (1–3), (4/5)
All infants <60 days (n¼ 902) 67.7 54.4 0.29 0.029
Infants 1–20 days (n¼ 878) 67.6 54.2 0.29 0.029
Infants 1–6 days (n¼ 613) 68.9 55.3 0.30 0.037
Infants 7–20 days (n¼ 265) 65.3 51.1 0.29 0.048
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a serum bilirubin levelX15 mg per 100 ml (260 mmol l1), based
on identification of jaundice of the distal extremities, including the
legs below the knees (Kramer level 4) or the palms and soles
(Kramer level 5). Thus, few infants with clinical signs of moderate
to severe hyperbilirubinemia would be missed, which in turn,
prevents long-term health-care costs due to the associated
morbidity and mortality resulting from untreated
hyperbilirubinemia.1
PHYs were better than HCWs at correctly ruling out moderate to
severe jaundice, thereby limiting the number of laboratory
evaluations or serum bilirubin measures performed at the tertiary
center. However, PHYs were also less sensitive in correctly
identifying infants 1 to 20 days with serum bilirubin levels
X15 mg per 100 ml (260 mmol l1). Once patients are identified
as having jaundice, referred by HCWs from peripheral primary care
clinics and overcome care seeking barriers to arrive at the tertiary
center for evaluation, a lower threshold of suspicion on the part
of the PHY, and thus for serum sampling for hyperbilirubinemia,
may be indicated.
This study suggests that HCWs trained in the clinical assessment
of jaundice have potential for improving the identification of
young infants who are at risk of severe consequences of
hyperbilirubinemia.13 Infants aged 1 to 20 days old with yellow
discoloration extending below the knees or to the palms on the
upper extremities should be considered at high risk of moderate to
severe hyperbilirubinemia and require referral to a tertiary setting
for further evaluation.
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